Registered title, quoted from ClinicalTrials.gov
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05482568, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Received >30 Gy chest radiation within 6 months prior to initial administration
Exclusion criterion 5
The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected
Exclusion criterion 8
Received systemic immunosuppressant therapy within 14 days prior to the first study
Exclusion criterion 9
Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter
Exclusion criterion 20
The ECOG score is 0 or 1
Inclusion criterion 3
There were active tuberculosis patients within 1 year before enrollment
Exclusion criterion 17
Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study
Exclusion criterion 24
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05482568, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Ability to give informed consent, signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements
- When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation
- The ECOG score is 0 or 1
- The expected survival is ≥12 weeks
- Subjects with advanced or metastatic non-small cell lung cancer
- Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided
- Subjects who have failed prior standard care or are intolerant to standard care
- There is at least one measurable lesion
- Vital organs are functioning well
- Heart function is good
- Agree to birth control
Exclusion Criteria:
- There are untreated or active central nervous system (CNS) tumor metastases
- Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration
- Systemic antitumor therapy was performed 4 weeks prior to study initiation
- Prior treatment with antibody-conjugated drugs
- Received >30 Gy chest radiation within 6 months prior to initial administration
- Palliative radiotherapy was completed within 7 days prior to initial administration
- Failure to recover from toxicity and/or complications of previous interventions to nCI-CTCAE ≤1
- The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected
- Received systemic immunosuppressant therapy within 14 days prior to the first study
- Subjects with known or suspected interstitial pneumonia
- In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration
- Presence of any active, known or suspected autoimmune disease
- Have poorly controlled or severe cardiovascular disease
- Previous or concurrent malignancy
- Subjects who developed a severe infection within 28 days prior to the first dose
- Active hepatitis B
- There were active tuberculosis patients within 1 year before enrollment
- There is a history of immunodeficiency
- Live attenuated vaccine was administered within 28 days prior to initial study administration or is expected to be administered during study treatment
- Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter
- Major surgery other than diagnosis or biopsy was performed within 28 days prior to initial administration
- People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316
- History of severe allergic reactions to other monoclonal antibody/fusion protein drugs
- Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study
- Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention
- Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable
Quoted from ClinicalTrials.gov, NCT05482568, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05482568, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.